Targeted therapy in BRAF  mutated aggressive papillary craniopharyngioma: a case report and overview of the literature

ConclusionsOur study confirms the excellent response of papillary craniopharyngioma to combined BRAF and MEK inhibitors. However, rapid tumor recurrence is the rule when medical therapy is stopped. Resistance to a second and third course of targeted therapy did not occur, suggesting that tumor mutations affecting the response to drugs seems an uncommon event in papillary craniopharyngioma. The exact role of targeted therapy in the treatment algorithm of papillary craniopharyngiomas has still to be refined.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research